Archive for November, 2006
« Previous EntriesCorcept Therapeutics Completes Enrollment In Third Phase 3 Study For Treating Psychotic Major Depression
Tuesday, November 14th, 2006Corcept Therapeutics Incorporated (Nasdaq: CORT) announced today that it completed patient enrollment in Study 06, the third of three Phase 3 clinical trials in which CORLUX(R) (mifepristone) is being evaluated for treating the psychotic features of psychotic major depression (PMD). The company expects to announce the results in late February 2007. [click link for full article]
New Treatment Strategy For The Prevention Of Recurrent Depression
Saturday, November 11th, 2006Some patients who experience recurrent depression may benefit from long-term maintenance treatment with anti-depressant medication, according to a new study led by a Virginia Commonwealth University researcher.Major depressive disorder is a recurrent condition that can have a profound impact on an individual’s quality of life. In the United States, approximately 17 percent of individuals will experience major depressive disorder during their lifetime. [click link for full article]
More Choice For Better Mental Health In UK
Friday, November 10th, 2006People with mental health problems will have more choice over their treatment under new guidance published by the Department of Health. The document, ‘Our Choices in Mental Health’, sets out the national framework that will make more choice available locally to people who use mental health services in England. [click link for full article]
Targacept Announces Positive Results Of Phase II Clinical Trial In Major Depression
Friday, November 10th, 2006Targacept, Inc. (Nasdaq: TRGT) today reported positive results from a double blind, placebo controlled Phase II clinical trial of mecamylamine hydrochloride as an augmentation treatment for major depression. The trial (n=184) evaluated the effects of mecamylamine taken with citalopram hydrobromide, a treatment combination known as TRIDMAC, in patients who did not respond adequately to citalopram alone. [click link for full article]
Barr Receives Tentative Approval For A Generic Version Of ZYPREXA(R) Zydis(R) Tablets, 5mg, 10mg, 15mg And 20mg
Friday, November 10th, 2006Barr Pharmaceuticals, Inc. (NYSE: BRL) today announced that its subsidiary, Barr Laboratories, Inc. has received tentative approval from the U.S. Food and Drug Administration (FDA) for its generic version of Eli Lilly and Company’s ZYPREXA(R) Zydis(R) (Olanzapine) Orally Disintegrating Tablets, 5mg, 10mg, 15mg and 20mg. The Company anticipates receiving final approval following the expiration of the 30-month stay in April 2007. [click link for full article]
Low Levels Of Neurotransmitter Serotonin May Perpetuate Child Abuse Across Generations
Wednesday, November 8th, 2006Infant abuse may be perpetuated between generations by changes in the brain induced by early experience, research shows at the University of Chicago shows.A research team found that when baby rhesus monkeys endured high rates of maternal rejection and mild abuse in their first month of life, their brains often produced less serotonin, a chemical that transmits impulses in the brain. [click link for full article]
New Depression Model Advances Disease Frontiers
Tuesday, November 7th, 2006A new study released today by the Centre for Addiction and Mental Heath (CAMH) provides a thorough explanation of how the “chemical imbalance” occurs in major depression, a disease that impacts approximately 5 percent of people globally. For over 30 years, scientists believed that monoamines — mood-related chemicals such as serotonin, norepinephrine and dopamine — are low in the brain during major depressive episodes. This is commonly referred to as a “chemical imbalance”. [click link for full article]
Key Brain Reward Region Not Activated By Positive Emotional Stimuli In Depression
Monday, November 6th, 2006Brain imaging researchers at Weill Cornell Medical College in New York City have demonstrated dysfunction in a key brain region in major depression. Major depression, a mood disorder affecting millions of people, causes tremendous suffering with a large impact on public health. Brain imaging has recently produced significant advances concerning brain circuitry in major depression, mostly focusing upon negative emotion and mood regulation. [click link for full article]
Significant Science Study May Lead To First Diagnostic Test To Guide Antidepressant Treatment
Monday, November 6th, 2006Treatment of depression is difficult for both patients and for psychiatrists. While there are numerous drugs available that work, finding the right one — or right combination — is, at times, a matter of trial and error. Studies released earlier this year demonstrated that around 60 percent of patients are not helped by the first drug they are given. [click link for full article]
Two-Thirds Of Depression Sufferers Can Be Helped With Carefully Monitored Treatment
Monday, November 6th, 2006More than two-thirds of people who suffer from major depression can become symptom-free if they are willing to work with their doctors and try various treatments to determine which work best for them, which may involve taking different antidepressants or adding cognitive therapy to the mix. [click link for full article]
« Previous Entries